Publications by authors named "Andres Forero-Torres"

68Publications

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

JAMA Oncol 2020 Jul 23. Epub 2020 Jul 23.

Berry Consultants, LLC, Austin, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.2535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378873PMC
July 2020

Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.

Surg Clin North Am 2018 Aug;98(4):773-785

Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, 1720 2nd Avenue South, NP 2501, Birmingham, AL 35294-3300, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suc.2018.04.004DOI Listing
August 2018

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.

Onco Targets Ther 2018 30;11:2399-2407. Epub 2018 Apr 30.

Department of Medicine, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S157331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935192PMC
April 2018

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia.

Clin Case Rep 2017 06 24;5(6):899-901. Epub 2017 Apr 24.

Department of Medicine University of Alabama at Birmingham Birmingham Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458012PMC
June 2017

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.

Curr Oncol Rep 2015 Sep;17(9):41

Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, 1720 2nd Avenue South, NP2540, Birmingham, AL, 35294, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0466-9DOI Listing
September 2015

Ultrasound imaging of breast tumor perfusion and neovascular morphology.

Ultrasound Med Biol 2015 Sep 24;41(9):2292-302. Epub 2015 Jun 24.

Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ultrasmedbio.2015.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526459PMC
September 2015

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Invest New Drugs 2014 Dec 22;32(6):1246-57. Epub 2014 Aug 22.

MD, FACP; MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1155 Pressler St, Unit 1374, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0151-0DOI Listing
December 2014

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

J Clin Oncol 2014 Oct 18;32(28):3137-43. Epub 2014 Aug 18.

Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner, Takeda Pharmaceuticals International, Cambridge, MA; Dana A. Kennedy, Seattle Genetics, Bothell; Andrei R. Shustov, University of Washington Medical Center, Seattle, WA; Andrew Davies, University of Southampton School of Medicine, Southampton; Tim Illidge, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.2456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171358PMC
October 2014

Effect of niclosamide on basal-like breast cancers.

Mol Cancer Ther 2014 Apr 19;13(4):800-11. Epub 2014 Feb 19.

Authors' Affiliations: Departments of Pathology, Biology, Biostatistics, Medicine, and Radiation Oncology; Division of Gynecologic Oncology; Southern Research Institute; and Division of Hematology and Onocology, University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981919PMC
April 2014

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Ther Adv Hematol 2012 Aug;3(4):209-25

Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/2040620712443076
Publisher Site
http://dx.doi.org/10.1177/2040620712443076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627331PMC
August 2012

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

Cancer Biother Radiopharm 2013 Jun 26;28(5):370-9. Epub 2013 Mar 26.

Department of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/cbr.2012.1387
Publisher Site
http://dx.doi.org/10.1089/cbr.2012.1387DOI Listing
June 2013

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.

Clin Cancer Res 2012 Jan 11;18(1):248-55. Epub 2011 Nov 11.

Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1425DOI Listing
January 2012

How do I treat "triple-negative" disease.

Curr Treat Options Oncol 2011 Dec;12(4):369-88

Comprehensive Cancer Center, University of Alabama at Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-011-0168-y
Publisher Site
http://dx.doi.org/10.1007/s11864-011-0168-yDOI Listing
December 2011

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.

Breast Cancer Res Treat 2012 Jun 14;133(2):437-45. Epub 2011 Sep 14.

Department of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-2182, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1763-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609658PMC
June 2012

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

N Engl J Med 2010 Nov;363(19):1812-21

Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/abs/10.1056/NEJMoa1002965
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1002965DOI Listing
November 2010

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.

Leuk Lymphoma 2010 Feb;51(2):228-35

Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428190903440946DOI Listing
February 2010

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

J Clin Oncol 2009 Sep 27;27(26):4371-7. Epub 2009 Jul 27.

Division of Oncology, Stanford University Medical Center, 875 Blake Wilbur Dr, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.3017DOI Listing
September 2009

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Br J Haematol 2009 Jul 19;146(2):171-9. Epub 2009 May 19.

University of Alabama at Birmingham, Comprehensive Cancer Center, 1824 Sixth Avenue South, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1365-2141.2009.07740.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2009.07740.xDOI Listing
July 2009

Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.

Clin Lymphoma Myeloma 2007 Dec;8 Suppl 1:S13-7

Department of Medicine, Division of Hematology & Oncology, University of Alabama at Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2007.s.028DOI Listing
December 2007

TRAIL-receptor antibodies as a potential cancer treatment.

Future Oncol 2007 Aug;3(4):405-9

Department of Radiation Oncology, Division of Radiation Biology, 1530 3rd Avenue South, WT1 674, Birmingham, AL 35294-6832, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/14796694.3.4.405
Publisher Site
http://dx.doi.org/10.2217/14796694.3.4.405DOI Listing
August 2007

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Cancer Biother Radiopharm 2005 Aug;20(4):379-90

Departments of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2005.20.379DOI Listing
August 2005

Diffuse F-18 FDG uptake in skeletal muscles secondary to chills resulting from sepsis: a cause for underestimation of viable tumor.

Clin Nucl Med 2004 Sep;29(9):600-1

Division of Nuclear Medicine, University of Alabama at Birmingham, Alabama 35249-6830, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.rlu.0000135801.03969.97DOI Listing
September 2004